<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852772</url>
  </required_header>
  <id_info>
    <org_study_id>AMR_2014-2</org_study_id>
    <nct_id>NCT02852772</nct_id>
  </id_info>
  <brief_title>Does Micro-albuminuria is a Predictive Factor for Cognitive Impairment in Persons Living With HIV (PLHIV) Who Achieve cART-sustained Immunovirological Control ?</brief_title>
  <acronym>ALCOVE</acronym>
  <official_title>Does Micro-albuminuria is a Predictive Factor for Cognitive Impairment in Persons Living With HIV (PLHIV) Who Achieve cART-sustained Immunovirological Control ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD), frequent in PLHIV, is a risk factor for cognitive impairment.&#xD;
      Micro-albuminuria is an early manifestation of CKD and a marker of vascular risk, notably&#xD;
      affecting the small vessels. In the older general population microalbuminuria is associated&#xD;
      with greater annual cognitive decline and has been proposed as an easily and inexpensive&#xD;
      measured marker predicting future cognitive function decline. Ageing of the PLH leads to an&#xD;
      increase of cognitive disorders and chronic renal failure incidence and could imply a common&#xD;
      underlying mechanism affecting the renal and cerebral microvasculature. In this setting the&#xD;
      investigators undertake this prospective, cross-sectional, case-control study to determine&#xD;
      whether the presence of a microalbuminuria at least 5 years ago in PLHs with sustained good&#xD;
      combination antiretroviral therapy (cART)-controlled immunovirological parameters could be a&#xD;
      marker predicting future cognitive impairment. They chose PLHs infected for at least 5 years&#xD;
      and with cART-sustained immunovirological control for at least 1 year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">November 7, 2016</completion_date>
  <primary_completion_date type="Actual">November 7, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Z-Score of five neurocognitive domains tested and global deficit score</measure>
    <time_frame>4 hours</time_frame>
    <description>Comparisons of composite cognitive scores (z-score) and scores of global cognitive deficits (GDS) between the two populations. The neuropsychological tests are made during a single consultation of a half day.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">82</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>PLHIV with microalbuminuria</arm_group_label>
    <description>Patient infected with HIV and well controlled by treatments, with microalbuminuria for at least 5 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLHIV without microalbuminuria (control)</arm_group_label>
    <description>Patient infected with HIV and well controlled by treatments, without microalbuminuria, matched for age +/- 5 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive function tests</intervention_name>
    <arm_group_label>PLHIV with microalbuminuria</arm_group_label>
    <arm_group_label>PLHIV without microalbuminuria (control)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients registered in the HIVREINE database (which combines nephrology and infectious&#xD;
        diseases services of AP-HP, Greater Paris University Hospitals)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known HIV infection for at least 5 years&#xD;
&#xD;
          -  Undetectable viral load under antiretroviral (ARV) treatment for at least 1 year,&#xD;
             regardless of the type of ARV&#xD;
&#xD;
          -  Number of CD4 â‰¥ 350, regardless of the CD4 nadir&#xD;
&#xD;
          -  Unopposed to participate to the study&#xD;
&#xD;
        For cases&#xD;
&#xD;
        - Micro-albuminuria defined by microalbuminuria / creatinuria between 3 and 30 mg/mmol&#xD;
&#xD;
        For controls, matched for age +/- 5 years - Absence of microalbuminuria defined by&#xD;
        microalbuminuria / creatinuria &lt;3 mg/mmol&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Known neurological disease, active or former&#xD;
&#xD;
          -  Active and regular use of drugs&#xD;
&#xD;
          -  Active Chronic alcoholism&#xD;
&#xD;
          -  Diabetes with known complications&#xD;
&#xD;
          -  Renal failure with glomerular filtration rate &lt;15 ml / min&#xD;
&#xD;
          -  Micro-albuminuria / creatinuria&gt; 30 mg / mmol&#xD;
&#xD;
          -  HIVAN&#xD;
&#xD;
          -  Unbalanced arterial hypertension&#xD;
&#xD;
          -  Patient did not have dosing glucose and lipid levels in over a year&#xD;
&#xD;
          -  Unaffiliated patient (or copyright holder) to a social security scheme&#xD;
&#xD;
          -  People enjoying a measure of legal protection Pregnant or breastfeeding&#xD;
&#xD;
        Secondary exclusion criteria&#xD;
&#xD;
        - Neurological disease found during the assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive impairment</keyword>
  <keyword>HIV</keyword>
  <keyword>Microalbuminuria</keyword>
  <keyword>Chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

